Top

Annals of Surgical Oncology

Published in:

01-05-2009 | ORIGINAL ARTICLE-TRANSLATIONAL RESEARCH AND BIOMARKERS

MDR1/P-gp and VEGF Synergistically Enhance the Invasion of Hep-2 Cells with Multidrug Resistance Induced by Taxol

Authors: Li Li, MD, PhD, Alice C. Jiang, BA, Pin Dong, MD, PhD, Haibo Wang, MD, Wei Xu, MD, PhD, Chengzhi Xu, MS

Published in: Annals of Surgical Oncology | Issue 5/2009

Abstract

Background

Tumor invasion/metastasis and multidrug resistance (MDR) are the main causes of treatment failure and high mortality in all kinds of cancer patients. The relationship between the two factors is still unclear. The aim of this study is to investigate the association between MDR and invasion, especially the role of multidrug resistance 1/P-glycoprotein (MDR1/P-gp) and vascular endothelial growth factor (VEGF) during the invasion.

Methods

Multidrug resistance 1 (MDR1) and VEGF receptor 2 (VEGFR-2) were detected with real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) and Western blotting at the levels of messenger RNA (mRNA) and protein, respectively. RNA interference was applied to inhibit the expression of MDR1. The invasive assays were performed with the CHEMICON cell invasion assay kit.

Results

The MDR cell line induced by Taxol (Hep-2T cell) was more invasive than its parent cell line (Hep-2 cell), which was at least in part mediated through the overexpressed MDR1/P-pg. MDR1-targeted RNA interference could effectively inhibit the expression of MDR1 and obviously decrease the invasive ability. Synergistic enhancing effects existed between MDR1/P-gp and VEGF on the invasion of Hep-2T cells. The expression of VEGFR-2 was elevated in Hep-2T cells. SU1498 could significantly decrease the invasion of Hep-2T cells. MDR1-targeted RNA interference and SU1498 had synergistic decreasing effect on the invasion of Hep-2T cells.

Conclusions

MDR1/P-pg may be a risk predictor for the invasion of laryngeal cancer. MDR1 knock down and VEGFR-2 inhibitor may be two promising treatment regiments for advanced laryngeal carcinoma patients with MDR and invasion/metastasis.

Liang Y, O’Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, et al. Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004;111:484–93.PubMedCrossRef

Liang Y, McDonnell S, Clynes M. Examining the relationship between cancer invasion/metastasis and drug resistance. Curr Cancer Drug Targets. 2002;2:257–77.PubMedCrossRef

Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.PubMedCrossRef

DeClerck YA, Imren S, Montgomery AM, et al. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol. 1997;425:89–97.PubMed

Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–33.PubMedCrossRef

Lamoreaux WJ, Fitzgerald ME, Reiner A, et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998;55:29–42.PubMedCrossRef

Liang Y, Meleady P, Cleary I, et al. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer. 2001;37:1041–52.PubMedCrossRef

Osmak M, Niksic D, Brozovic A, et al. Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis. Anticancer Res. 1999;19:3193–7.PubMed

Cillo C, Ling V, Hill RP. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability. Int J Cancer. 1989;43:107–11.PubMedCrossRef

10.

Cillo C, Dick JE, Ling V, et al. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. Cancer Res. 1987;47:2604–8.PubMed

11.

Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. 1996;56:2434–9.PubMed

12.

Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med. 1993;328:184–94.PubMedCrossRef

13.

O-charoenrat P, Modjtahedi H, Rhys-Evans P, et al. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res. 2000;60:1121–8.PubMed

14.

Li L, Jiang AC, Dong P, et al. The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol. Otolaryngol Head Neck Surg. 2007;137:659–64.PubMedCrossRef

15.

Miletti-Gonzalez KE, Chen S, Muthukumaran N, et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res. 2005;65:6660–7.PubMedCrossRef

16.

Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63:1515–9.PubMed

17.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.PubMedCrossRef

18.

Boguslawski G, McGlynn PW, Harvey KA, et al. SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem. 2004;279:5716–24.PubMedCrossRef

19.

Crown J, O’Leary M. The taxanes: an update. Lancet. 2000;355:1176–8.PubMedCrossRef

20.

Glisson BS, Murphy BA, Frenette G, et al. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002;20:1593–9.PubMedCrossRef

21.

Morozevich GE, Kozlova NI, Preobrazhenskaya ME, et al. The role of beta1 integrin subfamily in anchorage-dependent apoptosis of breast carcinoma cells differing in multidrug resistance. Biochemistry (Mosc). 2006;71:489–95.CrossRef

22.

Yang JM, Xu Z, Wu H, et al. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res. 2003;1:420–7.PubMed

23.

Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991;51:2720–6.PubMed

24.

Schneider J, Gonzalez-Roces S, Pollan M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res. 2001;3:183–91.PubMedCrossRef

25.

Yabushita H, Shimazu M, Noguchi M, et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep. 2003;10:89–95.PubMed

26.

Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, et al. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol. 2003;171:4340–51.PubMed

27.

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.PubMedCrossRef

28.

Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22.PubMed

29.

Wang Y, Kong W, Yue J, et al. Vascular endothelial growth factor165-regulated nasopharyngeal carcinoma cell lines invasion and migration involve expression and activation of matrix metalloproteinase-2. J Huazhong Univ Sci Technolog Med Sci. 2006;26:621–4.PubMedCrossRef

30.

Wang FQ, So J, Reierstad S, et al. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer. 2006;118:879–88.PubMedCrossRef

31.

Sauter ER, Nesbit M, Watson JC, et al. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 1999;5:775–82.PubMed

32.

Tao L, Zhou L, Zheng L, et al. Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo. Cancer Chemother Pharmacol. 2006;58:24–34.PubMedCrossRef

33.

Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–5.PubMed

34.

Kyzas PA, Stefanou D, Batistatou A, et al. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol. 2005;18:485–94.PubMedCrossRef

35.

Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res. 2002;8:221–32.PubMed

Title: MDR1/P-gp and VEGF Synergistically Enhance the Invasion of Hep-2 Cells with Multidrug Resistance Induced by Taxol
Authors: Li Li, MD, PhD
Alice C. Jiang, BA
Pin Dong, MD, PhD
Haibo Wang, MD
Wei Xu, MD, PhD
Chengzhi Xu, MS
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 5/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0395-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MDR1/P-gp and VEGF Synergistically Enhance the Invasion of Hep-2 Cells with Multidrug Resistance Induced by Taxol

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2009

Comment on “Extra-Intestinal Manifestations of Familial Adenomatous Polyposis”

Good Prediction of the Likelihood for Sentinel Lymph Node Metastasis by Using the MSKCC Nomogram in a German Breast Cancer Population

Feasibility and Efficacy of Accelerated Weekly Concomitant Boost Postoperative Radiation Therapy Combined with Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

Validation of a Nomogram to Predict the Risk of Nonsentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node Biopsy: Validation of the MSKCC Breast Nomogram

Modified Wise-Pattern Reduction Mammaplasty, a New Tool for Upper Quadrantectomies: A Preliminary Report

Microscopic Satellites Around a Primary Melanoma: Another Piece of the Puzzle in Melanoma Staging